| Autor: |
Fotopoulou C; Gynecologic oncology, Hammersmith Hospital, London, UK chfotopoulou@gmail.com., Eriksson AG; Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo, Norway.; The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Planchamp F; Institut Bergonie, Bordeaux, France., Morice P; Surgery, Gustave Roussy, Villejuif, Île-de-France, France.; Paris-South University/Paris Saclay, Paris, Île-de-France, France., Taylor A; Gynaecology Oncology, Royal Marsden Hospital, London, UK., Sturdza A; Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria., Florin Coza O; Iuliu Hagieganu University of Medicine and Pharmacy Faculty of Medicine, Cluj Napoca, Romania.; Oncology Institute 'Prof. Dr.I.Chiricuta', Cluj Napoca, Romania., Halaska MJ; Dept. of Obstetrics and Gynaecology, 3rd Medical Faculty, Charles University, Prague, Czech Republic., Martinelli F; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Armbrust R; Dept. of Gynecology, Charite University Hospital Berlin, Berlin, Germany., Chargari C; Hôpital Universitaire Pitié Salpêtrière, Paris, Île-de-France, France. |
| Abstrakt: |
Competing Interests: Competing interests: CF has reported being on the advisory board for Roche, Tesaro, GSK, MSD/AZ, and Clovis; AT has reported grants for travelling from MSD; AS has reported grants for travelling from Medical University of Vienna; RA has reported grants for travelling from GSK, Roche, MSD and Novocure; CC has reported advisory boards for GSK, MSD and Eisai; AGZE, FP, PM, OFC, MJH and FM have reported no conflicts of interest. |
